Additionally, antibodies against FGFR ligands, including anti-FGF2 mAb 3F12E7, and antibodies targeting FGF8b or FGF19, are being investigated as therapeutic approaches to inhibit tumor growth [12,215]. This evidence concerns the gene FGF2 and neoplasm.